• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

偏头痛的发病机制及药物治疗选择状况

Migraine pathogenesis and state of pharmacological treatment options.

作者信息

Sprenger Till, Goadsby Peter J

机构信息

UCSF Headache Group-Department of Neurology, University of California, San Francisco, CA, USA.

出版信息

BMC Med. 2009 Nov 16;7:71. doi: 10.1186/1741-7015-7-71.

DOI:10.1186/1741-7015-7-71
PMID:19917094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2784479/
Abstract

Migraine is a largely inherited disorder of the brain characterized by a complex, but stereotypical, dysfunction of sensory processing. Often the most obvious clinical symptom is head pain, but non-headache symptoms such as photophobia, phonophobia and nausea are clearly part of the typical presentation. This review discusses the current pathophysiological concepts of migraine and migraine aura, such as a possible brainstem dysfunction and cortical spreading depression. Acute and preventive migraine treatment approaches are briefly covered with a focus on shortcomings of the currently available treatment options. A number of different receptors, such as calcitonin gene-related peptide (CGRP), TRPV1 and glutamate receptors, are currently being targeted by potential novel migraine therapeutics. The prospects of this research are exciting and are likely to improve patient care.

摘要

偏头痛是一种主要由遗传导致的脑部疾病,其特征是感觉处理功能出现复杂但刻板的功能障碍。通常最明显的临床症状是头痛,但诸如畏光、畏声和恶心等非头痛症状显然也是典型症状的一部分。本综述讨论了偏头痛和偏头痛先兆目前的病理生理概念,例如可能存在的脑干功能障碍和皮层扩散性抑制。简要介绍了急性和预防性偏头痛的治疗方法,并重点关注了现有治疗方案的缺点。目前一些潜在的新型偏头痛治疗药物正针对多种不同的受体,如降钙素基因相关肽(CGRP)、瞬时受体电位香草酸亚型1(TRPV1)和谷氨酸受体。这项研究的前景令人兴奋,很可能会改善患者的治疗效果。

相似文献

1
Migraine pathogenesis and state of pharmacological treatment options.偏头痛的发病机制及药物治疗选择状况
BMC Med. 2009 Nov 16;7:71. doi: 10.1186/1741-7015-7-71.
2
Basic mechanisms of migraine and its acute treatment.偏头痛的基本机制及其急性治疗。
Pharmacol Ther. 2012 Dec;136(3):319-33. doi: 10.1016/j.pharmthera.2012.08.011. Epub 2012 Aug 24.
3
[Migraine: advances in the pathophysiology and treatment].[偏头痛:病理生理学与治疗的进展]
Rinsho Shinkeigaku. 2011 Feb;51(2):103-9. doi: 10.5692/clinicalneurol.51.103.
4
Role of CGRP in Migraine.降钙素基因相关肽在偏头痛中的作用。
Handb Exp Pharmacol. 2019;255:121-130. doi: 10.1007/164_2018_201.
5
Current and novel insights into the neurophysiology of migraine and its implications for therapeutics.偏头痛神经生理学的当前和新见解及其对治疗的意义。
Pharmacol Ther. 2017 Apr;172:151-170. doi: 10.1016/j.pharmthera.2016.12.005. Epub 2016 Dec 2.
6
Migraine with brainstem aura: Why not a cortical origin?偏头痛伴脑干先兆:皮质起源为何不可?
Cephalalgia. 2018 Sep;38(10):1687-1695. doi: 10.1177/0333102417738251. Epub 2017 Oct 26.
7
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.偏头痛的药物治疗:除曲普坦类药物外的 CGRP 和 5-HT。
Pharmacol Ther. 2020 Jul;211:107528. doi: 10.1016/j.pharmthera.2020.107528. Epub 2020 Mar 12.
8
Migraine is a neuronal disease.偏头痛是一种神经元疾病。
J Neural Transm (Vienna). 2011 Apr;118(4):511-24. doi: 10.1007/s00702-010-0515-3. Epub 2010 Dec 15.
9
The role of the brainstem in migraine: Potential brainstem effects of CGRP and CGRP receptor activation in animal models.脑干在偏头痛中的作用:动物模型中 CGRP 和 CGRP 受体激活的潜在脑干效应。
Cephalalgia. 2019 Mar;39(3):390-402. doi: 10.1177/0333102418756863. Epub 2018 Feb 7.
10
New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.偏头痛代谢和遗传基础的新见解:对管理和治疗方法的新影响。
Int J Mol Sci. 2022 Mar 11;23(6):3018. doi: 10.3390/ijms23063018.

引用本文的文献

1
Quickest way to less headache days: an operational research model and its implementation for chronic migraine.减少头痛天数的最快方法:一种针对慢性偏头痛的运筹学模型及其应用
BMC Neurol. 2025 Mar 31;25(1):132. doi: 10.1186/s12883-025-04124-5.
2
Prospective Matched Case-Control Study of Over-Early P100 Wave Latency in Migraine with Aura.伴先兆偏头痛患者P100波潜伏期过早的前瞻性配对病例对照研究
Biomedicines. 2023 Nov 6;11(11):2979. doi: 10.3390/biomedicines11112979.
3
Trends in utilization and costs of migraine medications, 2017-2020.偏头痛药物的使用和费用趋势,2017-2020 年。
J Headache Pain. 2022 Aug 28;23(1):111. doi: 10.1186/s10194-022-01476-y.
4
Neuropeptide changes in an improved migraine model with repeat stimulations.重复刺激改善偏头痛模型中的神经肽变化
Transl Neurosci. 2021 Dec 9;12(1):523-532. doi: 10.1515/tnsci-2020-0201. eCollection 2021 Jan 1.
5
The Association Between Blood Pressure and Headache in Postmenopausal Women: A Prospective Hospital-Based Study.绝经后女性血压与头痛之间的关联:一项基于医院的前瞻性研究。
Int J Gen Med. 2021 Jun 16;14:2563-2568. doi: 10.2147/IJGM.S317780. eCollection 2021.
6
Association of dietary diversity score (DDS) and migraine headache severity among women.饮食多样性评分(DDS)与女性偏头痛严重程度的关联。
Neurol Sci. 2021 Aug;42(8):3403-3410. doi: 10.1007/s10072-020-04982-6. Epub 2021 Jan 11.
7
Cortical potentiation induced by calcitonin gene-related peptide (CGRP) in the insular cortex of adult mice.降钙素基因相关肽(CGRP)诱导成年小鼠岛叶皮层的皮质兴奋。
Mol Brain. 2020 Mar 9;13(1):36. doi: 10.1186/s13041-020-00580-x.
8
Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.左乙拉西坦作为成人偏头痛的预防治疗:最新的系统评价和定量荟萃分析。
Eur J Clin Pharmacol. 2020 Feb;76(2):161-174. doi: 10.1007/s00228-019-02790-2. Epub 2019 Nov 25.
9
Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention.酮体在偏头痛预防中的潜在保护机制。
Nutrients. 2019 Apr 10;11(4):811. doi: 10.3390/nu11040811.
10
Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.外源性酮体预防性治疗偏头痛的疗效与安全性:一项单中心、随机、安慰剂对照、双盲交叉试验的研究方案
Trials. 2019 Jan 17;20(1):61. doi: 10.1186/s13063-018-3120-7.

本文引用的文献

1
Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study.托纳贝萨特对伴先兆偏头痛的影响:一项随机、双盲、安慰剂对照的交叉研究。
Lancet Neurol. 2009 Aug;8(8):718-23. doi: 10.1016/S1474-4422(09)70135-8. Epub 2009 Jun 29.
2
Phenotype-driven preventive strategies for migraine and other headaches.针对偏头痛及其他头痛的表型驱动预防策略。
Neurologist. 2009 Mar;15(2):59-70. doi: 10.1097/NRL.0b013e318165eb94.
3
Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.皮质扩散性抑制抑制剂托纳博沙用于偏头痛预防的随机、双盲、安慰剂对照概念验证研究
Cephalalgia. 2009 Jul;29(7):742-50. doi: 10.1111/j.1468-2982.2008.01804.x. Epub 2009 Feb 13.
4
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.降钙素基因相关肽受体新型口服拮抗剂MK-0974(替卡普坦)与佐米曲普坦治疗急性偏头痛的疗效及耐受性比较:一项随机、安慰剂对照、平行治疗试验
Lancet. 2008 Dec 20;372(9656):2115-23. doi: 10.1016/S0140-6736(08)61626-8. Epub 2008 Nov 25.
5
Are cortical spreading depression and headache in migraine causally linked?偏头痛中的皮层扩散性抑制与头痛存在因果联系吗?
Cephalalgia. 2009 Feb;29(2):244-9. doi: 10.1111/j.1468-2982.2008.01713.x. Epub 2008 Nov 18.
6
Is migraine a genetic illness? The various forms of migraine share a common genetic cause.偏头痛是一种遗传性疾病吗?各种形式的偏头痛都有一个共同的遗传病因。
Neurol Sci. 2008 May;29 Suppl 1:S52-4. doi: 10.1007/s10072-008-0887-4.
7
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.血管活性肠肽可引起明显的头部血管扩张,但不会诱发偏头痛。
Cephalalgia. 2008 Mar;28(3):226-36. doi: 10.1111/j.1468-2982.2007.01497.x.
8
Emerging therapies for migraine.偏头痛的新兴疗法。
Nat Clin Pract Neurol. 2007 Nov;3(11):610-9. doi: 10.1038/ncpneuro0639.
9
A pharmacogenomic evaluation of migraine therapy.偏头痛治疗的药物基因组学评估。
Expert Opin Pharmacother. 2007 Aug;8(12):1821-35. doi: 10.1517/14656566.8.12.1821.
10
Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms.1000毫克泡腾阿司匹林的疗效与安全性:偏头痛及偏头痛伴随症状三项试验的个体患者数据荟萃分析
J Neurol. 2007 Jun;254(6):705-12. doi: 10.1007/s00415-007-0547-2. Epub 2007 Apr 10.